换一批
换一批Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.
作者：
Ami,Aoki [1]
;
Chiaki,Iwamura [2]
;
Masahiro,Kiuchi [3]
;
Kaori,Tsuji [3]
;
Atsushi,Sasaki [3]
;
Takahisa,Hishiya [3]
;
Rui,Hirasawa [3]
;
Kota,Kokubo [3]
;
Sachiko,Kuriyama [3]
;
Atsushi,Onodera [3]
;
Tadanaga,Shimada [4]
;
Tetsutaro,Nagaoka [5]
;
Satoru,Ishikawa [6]
;
Akira,Kojima [6]
;
Haruki,Mito [7]
;
Ryota,Hase [7]
;
Yasunori,Kasahara [8]
;
Naohide,Kuriyama [9]
;
Sukeyuki,Nakamura [10]
;
Takashi,Urushibara [11]
;
Satoru,Kaneda [12]
;
Seiichiro,Sakao [13]
;
Osamu,Nishida [9]
;
Kazuhisa,Takahashi [5]
;
Motoko Y,Kimura [14]
;
Shinichiro,Motohashi [15]
;
Hidetoshi,Igari [16]
;
Yuzuru,Ikehara [17]
;
Hiroshi,Nakajima [18]
;
Takuji,Suzuki [19]
;
Hideki,Hanaoka [20]
;
Taka-Aki,Nakada [4]
;
Toshiaki,Kikuchi [21]
;
Toshinori,Nakayama [22]
;
Koutaro,Yokote [23]
;
Kiyoshi,Hirahara [24]
作者单位：
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.;Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8510, Japan.
[1]
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.;Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
[2]
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[3]
Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[4]
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, 113-8431, Japan.
[5]
Funabashi Central Hospital, Chiba, 273-8556, Japan.
[6]
Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, 286-0041, Japan.
[7]
Department of Respiratory Medicine, Eastern Chiba Medical Center, Chiba, 283-8686, Japan.
[8]
Department of Anesthesiology and Critical Care Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, 470-1192, Japan.
[9]
Funabashi Municipal Medical Center, Chiba, 273-8588, Japan.
[10]
Kimitsu Chuo Hospital, Chiba, 292-0822, Japan.
[11]
Department of Gastroenterology, NHO Chiba Medical Center, Chiba, 260-8606, Japan.
[12]
Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Chiba, 286-8520, Japan.
[13]
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.;Department of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[14]
Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[15]
Department of Infectious Diseases, Chiba University Hospital, Chiba, 260-8677, Japan.;COVID-19 Vaccine Center, Chiba University Hospital, Chiba, 260-8677, Japan.
[16]
Department of Pathology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[17]
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.;COVID-19 Vaccine Center, Chiba University Hospital, Chiba, 260-8677, Japan.;Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[18]
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.;Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[19]
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.;Clinical Research Center, Chiba University Hospital, Chiba, 260-8677, Japan.
[20]
Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8510, Japan.
[21]
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. tnakayama@faculty.chiba-u.jp.;AMED-CREST, AMED, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. tnakayama@faculty.chiba-u.jp.
[22]
Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
[23]
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. hiraharak@chiba-u.jp.;Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan. hiraharak@chiba-u.jp.;AMED-CREST, AMED, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. hiraharak@chiba-u.jp.
[24]
主题词
女(雌)性(Female);人类(Humans);男(雄)性(Male);自身抗体(Autoantibodies);树突细胞(Dendritic Cells);干扰素Ⅰ型(Interferon Type I);髓系细胞(Myeloid Cells);疾病严重程度指数(Severity of Illness Index);信号传导(Signal Transduction)
DOI
10.1007/s10875-024-01708-7
PMID
38647550
发布时间
2024-12-04
- 浏览0
Journal of clinical immunology
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
